Biomarkers and surrogate end points in clinical trials of tuberculosis treatment [3]

Journal of Infectious Diseases

Volumn 196, Issue 4, 2007, Pages 648-649

  Davies, Geraint Rhys ^a   Phillips, Patrick P J ^b   Nunn, Andrew J ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; NEW DRUG; TUBERCULOSTATIC AGENT;

BACTERIUM CULTURE; CD4 LYMPHOCYTE COUNT; CLINICAL RESEARCH; CLINICAL STUDY; DISEASE MARKER; DRUG TREATMENT FAILURE; HUMAN; LETTER; PRIORITY JOURNAL; RELAPSE; TREATMENT RESPONSE; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; BIOLOGICAL MARKERS; CLINICAL TRIALS; HUMANS; RECURRENCE; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 34547632574     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/519744     Document Type: Letter

References (8)

1. Mistry R, Cliff JM, Clayton CL, et al. Gene expression patterns in whole blood identify subjects at risk for recurrent tuberculosis. J Infect Dis 2007; 195:357-65.
2. Aber VR, Nunn AJ. Factors affecting relapse following short-course chemotherapy. Bull Int Union Tuberc 1978; 53:260-4.
3. Mitchison DA. Modern methods for assessing the drugs used in the chemotherapy of mycobacterial disease. Soc Appl Bacteriol Symp Ser 1996; 25:72S-80S.
4. Molenberghs G, Burzykowski T, Alonso A, Buyse M. A perspective on surrogate endpoints in controlled clinical trials. Stat Methods Med Res 2004; 13:177-206.
5. Baker SG, Kramer BS. A perfect correlate does not a surrogate make. BMC Med Res Methodol 2003; 3:16.
6. Hughes MD, Daniels MJ, Fischl MA, Kim S, Schooley RT. CD4 cell count as a surrogate endpoint in HIV clinical trials: a meta-analysis of studies of the AIDS Clinical Trials Group. AIDS 1998; 12:1823-32.
7. Delta Coordinating Committee and Virology Group. An evaluation of HIV RNA and CD4 cell count as surrogates for clinical outcome. AIDS 1999; 13:565-73.
8. HIV Surrogate Marker Collaborative Group. Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: a meta-analysis. AIDS Res Hum Retroviruses 2000; 16:1123-33.